Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol.

ABSTRACT:

Rationale & objective

Mineral and bone disorder in chronic kidney disease (CKD) is associated with progression of coronary artery calcification (CAC). Mineral and bone disorder often is treated with calcitriol and other vitamin D receptor activators, including paricalcitol, agents that may have differential effects on calcium, phosphate, and parathyroid hormone levels. Accordingly, we investigated whether these agents have differential effects on CAC progression in patients with CKD.

Study design

Randomized, double-concealed, 48-week clinical trial.

Setting & participants

CKD stage 3 or 4 with secondary hyperparathyroidism with CAC score > 0 and no prior treatment with activated vitamin D.

Intervention

Calcitriol versus paricalcitol.

Outcomes

The primary

SUBMITTER: Anis KH 

PROVIDER: S-EPMC7406841 | biostudies-literature | 2020 Jul-Aug

REPOSITORIES: biostudies-literature